A panel of international experts was convened by the Infectious Diseases Society of America in collaboration with the European Society for Microbiology and Infectious Diseases to update the 1999 uncomplicated urinary tract infection (UTI) guidelines. The focus of the recommendations is on women with uncomplicated cystitis and pyelonephritis. Since the 1999 guideline, antimicrobial resistance among uropathogens causing urinary tract infections has increased, and newer agents and different duration of therapy have been studied. This update reflects many of the changes since the 1999 guideline.
From the Northeastern Ohio Universities College of Medicine and Pharmacy, Rootstown and Summa Health System, Akron, OH.
Correspondence to: Thomas M. File Jr, MD, 75 Arch St, Suite 506 (Main Office; Suite 105 for Research), Akron, OH 44304. E-mail: email@example.com.
The author discloses that he has received recent research funding from Cerexa/Forest, Pfizer, Boehringer Ingelheim, Gilead, GlaxoSmithKline, and Tibotec; and he is a consultant for Cerexa/Forest, Merck, Nabriva, Pfizer, and Tetraphase.